



Patient Enrollment Form for PALYNZIQ® (pegvaliase-pqz) Injection

Fax completed form with prescriber's signature to **1.888.863.3361**
 To learn more about BioMarin RareConnections™ call **1-866-906-6100**,
 hours **M–F, 8 AM–8 PM (ET)**



All required fields are purple and bolded

PATIENT	First Name	Middle Initial	Last Name	Suffix	
	Date of Birth (mm/dd/yyyy)	Gender <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Other			
	Address			Floor/Suite/Unit	
	City			State ZIP Code	
	Primary Phone	Mobile Phone <input type="checkbox"/> (same as primary)	Email		
	Preferred Method of Contact <input type="checkbox"/> Primary Phone <input type="checkbox"/> Mobile Phone <input type="checkbox"/> Email		Preferred Language: <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other language (please specify)		
	Authorized Representative Name (if applicable)			Relationship to Patient	
Phone		Email			
PRESCRIBER	First Name		Last Name		
	Specialty		NPI Number		
	State License Number		Medicaid Number	Tax ID	
	Name of Institution/Practice				
	Address			Floor/Suite/Unit	
	City			State	ZIP Code
	Phone	Fax	Email		
	Preferred Method of Contact <input type="checkbox"/> Phone <input type="checkbox"/> Fax <input type="checkbox"/> Email				
Primary Contact Name (if different from prescriber)					
Phone		Fax	Email		
INSURANCE	Provide copies of all medical and prescription cards — front and back				
	<input type="checkbox"/> Patient has no insurance				
	Primary Medical Insurance Name			Insurance Phone	
	Subscriber Name		Relationship to Patient		
	Member ID	Group		Plan Code	
	Prescription (PBM) Insurance Name			Insurance Phone	
	Subscriber Name				
Member ID	RxBIN	RxPCN	RxGROUP		

Patient's Full Name	Date of birth (mm/dd/yyyy)
----------------------------	-----------------------------------

DIAGNOSIS / CLINICAL	Diagnosis ICD-10-CM*		Baseline Blood Phe Level
	<input type="checkbox"/> Classical Phenylketonuria (PKU) E70.0 <input type="checkbox"/> Other Hyperphenylalaninemias E70.1 <input type="checkbox"/> Other diagnosis (<i>please specify</i>) _____		Date
	Prolonged elevated blood phenylalanine (Phe) can result in neurocognitive and neuropsychiatric impairment. I am prescribing PALYNZIQ for this patient and find it medically necessary to reduce blood Phe levels for this patient.		
	Additional comments		
	Patient allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Yes (please list) _____		
Concurrent medications			

Please complete either right or left treatment sections for each row								
Instructions: Please check box for each dose prescribed								
PRESCRIPTION	Recommended Dosing for PALYNZIQ® (pegvaliase-ppqz) Injection Therapy				Customized Dosing for PALYNZIQ® (pegvaliase-ppqz) Injection Therapy			
	Treatment	PALYNZIQ Prescription	Quantity	Refills	Treatment	PALYNZIQ Prescription	Quantity	Refills
	Induction/Titration	<input type="checkbox"/> Inject 2.5 mg (0.5 mL) SubQ • Once weekly for 4 weeks, then • Twice weekly for 1 week	$\frac{6}{2.5 \text{ mg (0.5 mL)}}$	Not Applicable	Induction/Titration	<input type="checkbox"/> Inject _____ mg SubQ Frequency _____		
	Titration	<input type="checkbox"/> Inject 10 mg (0.5 mL) SubQ • Once weekly for 1 week, then • Twice weekly for 1 week, then • Four times a week for 1 week, then • Once daily for 1 week	$\frac{14}{10 \text{ mg (0.5 mL)}}$	Not Applicable	Titration	<input type="checkbox"/> Inject _____ mg SubQ Frequency _____		
	Maintenance	<input type="checkbox"/> Inject 20 mg (1 mL) SubQ • Daily for a minimum of 24 weeks	$\frac{30}{20 \text{ mg (1 mL)}}$	5	Maintenance	<input type="checkbox"/> Inject _____ mg SubQ Frequency _____		
	Maintenance	<input type="checkbox"/> Inject 40 mg (2 × 20 mg [1 mL]) SubQ • Daily for a minimum of 16 weeks	$\frac{60}{20 \text{ mg (1 mL)}}$	3	Maintenance	<input type="checkbox"/> Inject _____ mg SubQ Frequency _____		
Maximum	<input type="checkbox"/> Inject 60 mg (3 × 20 mg [1 mL]) SubQ • Daily for a maximum of 16 weeks	$\frac{90}{20 \text{ mg (1 mL)}}$	3	Maximum	<input type="checkbox"/> Inject _____ mg SubQ Frequency _____			
Epinephrine Prescription Confirmation* Patient has possession of epinephrine? <input type="checkbox"/> Yes <input type="checkbox"/> No If No, epinephrine prescription will be filled as follows (check one): <input type="checkbox"/> At local retail pharmacy (prescription given to patient) <input type="checkbox"/> At Specialty Pharmacy (attached to this prescription)								
Ancillary Supplies —Specialty Pharmacy will provide the following items to patients on first dispense and as needed thereafter: Sharps Container, Alcohol wipes and Band-Aids.								
Premedication Prescriptions: If applicable, please make a selection below. Will patient require additional premedication prescriptions? <input type="checkbox"/> Yes <input type="checkbox"/> No Premedication prescriptions will be filled as follows (check one): <input type="checkbox"/> At local retail pharmacy (prescription given to patient) <input type="checkbox"/> At Specialty Pharmacy (attached to this prescription)								
Special Delivery Instructions								

LOGISTICS	For Clinic Shipments Only Check the box and provide information below for clinic shipments (if applicable, for initial doses)						
	<input type="checkbox"/> Ship to clinic address below. The Specialty Pharmacy will contact the prescriber/clinic to coordinate shipment.						
	Clinic Point of Contact		Clinic Point-of-Contact Phone		Clinic Point-of-Contact Email		
	Shipping Address					State	ZIP Code
Special Delivery Instructions							

PRESCRIBER DECLARATION	Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed PALYNZIQ based on my professional judgment of medical necessity. I authorize BioMarin Pharmaceutical Inc., its affiliates, agents, and contractors (collectively, "BioMarin") to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the above-named patient utilizing their benefit plan. I also authorize the BioMarin RareConnections™ program to perform any steps necessary to secure reimbursement for PALYNZIQ, including but not limited to insurance verification and case assessment. I understand that BioMarin or BioMarin RareConnections may need additional information, and I agree to provide it as needed for the purposes of securing reimbursement.									
	Prescriber's Signature. Please make a selection <table style="width:100%; border: none;"> <tr> <td style="width:45%; border: none;">Prescriber's Signature/Dispense as Written (no stamps or initials)</td> <td style="width:10%; border: none;">Date</td> <td style="width:45%; border: none;">Prescriber's Signature/Substitution Permitted (no stamps or initials)</td> <td style="width:10%; border: none;">Date</td> </tr> </table>							Prescriber's Signature/Dispense as Written (no stamps or initials)	Date	Prescriber's Signature/Substitution Permitted (no stamps or initials)
Prescriber's Signature/Dispense as Written (no stamps or initials)	Date	Prescriber's Signature/Substitution Permitted (no stamps or initials)	Date							

GETTING YOUR PATIENT STARTED WITH PALYNZIQ

PALYNZIQ[®] (pegvaliase-pqpz) Injection is only available via Specialty Pharmacy by using the PALYNZIQ BioMarin RareConnections[™] Patient Enrollment Form

Complete the PALYNZIQ BioMarin RareConnections Patient Enrollment Form in its entirety and fax both pages to 1.888.863.3361

Every effort is made to limit the number of calls to your office. Please ensure that:

- All fields are complete
- Patient has signed a BioMarin RareConnections Patient Consent Form (PCF)
- Prescription information is complete
- For all dose adjustments after the initial PALYNZIQ Patient Enrollment Form has been completed, a new prescription or verbal prescription is needed
- Attach all additional prescriptions to this document if Specialty Pharmacy is to fill

Upon receipt of the completed PALYNZIQ BioMarin RareConnections Patient Enrollment Form, BioMarin RareConnections will help to confirm coverage with your patient's health plan

BioMarin RareConnections may contact your office via phone, fax, or email to:

- Obtain any required information that was left off the PALYNZIQ BioMarin RareConnections Patient Enrollment Form
- Obtain additional information required by insurance companies

Please advise your patient that a Specialty Pharmacy will be calling to help coordinate delivery of the PALYNZIQ prescription

- The Specialty Pharmacy will contact your patient/clinic to obtain a verbal confirmation of the delivery address prior to mailing the medication
- The Specialty Pharmacy will confirm patient need for all selected ancillary supplies prior to each shipment
- The Specialty Pharmacy will verify REMS* clinic certification and patient enrollment prior to each shipment
- Premedication will require a separate prescription if the Specialty Pharmacy is to fill prescription
- Epinephrine prescription via this form or sent separately will be needed if Specialty Pharmacy is to fill prescription

	TREATMENT	PALYNZIQ DOSAGE	DURATION [†]
RECOMMENDED DOSING REGIMEN	Induction	2.5 mg once weekly	4 weeks
	Titration	2.5 mg twice weekly	1 week
		10 mg once weekly	1 week
		10 mg twice weekly	1 week
		10 mg four times per week	1 week
		10 mg once daily	1 week
	Maintenance [‡]	20 mg once daily	24 weeks
		40 mg once daily	16 weeks
	Maximum [§]	60 mg once daily	16 weeks

*REMS: Risk Evaluation and Mitigation Strategy.

†Additional time may be required prior to each dosage escalation based on patient tolerability.

‡Individualize treatment to the lowest effective and tolerated dosage. Consider increasing to 40 mg once daily in patients who have not achieved a response with 20 mg once daily continuous treatment for at least 24 weeks. Consider increasing to a maximum of 60 mg once daily in patients who have not achieved a response with 40 mg once daily continuous treatment for at least 16 weeks (see Clinical Studies [14] section of Prescribing Information).

§Discontinue PALYNZIQ in patients who have not achieved an adequate response after 16 weeks of continuous treatment at the maximum dosage of 60 mg once daily.

PATIENT CONSENT FORM

To learn more about BioMarin RareConnections™
call 1.866.906.6100, hours M–F, 8 AM–8 PM (ET)



References to “you,” “your,” “I,” “me,” “my,” etc. in this form are to the patient, even if an authorized representative is signing this form on the patient’s behalf.

FOR BIOMARIN TO ASSIST YOU WITH ITS MEDICINES AND RELATED CARE, YOU WILL NEED TO PROVIDE CONSENT TO BOTH YOUR HEALTHCARE PROVIDER AND BIOMARIN:

- Your healthcare provider needs your written consent to release your protected health information (PHI) to BioMarin
- BioMarin needs your written consent to share your information with service providers such as laboratories and pharmacies to assist you with accessing services that support your treatment
- BioMarin needs your consent to contact you with marketing and other communications about BioMarin’s products, services, programs, and other topics of interest for marketing, educational, or other purposes; to assist you in getting help through additional services that support your treatment plan; and to allow you to provide feedback to BioMarin through market research
- As described below, your consent is voluntary and is not required for treatment, medications, or other care. Your consent is required for BioMarin to provide the product support services described here
- BioMarin and its agents and representatives do not work under the direction of your healthcare provider or give medical advice; they are trained to direct patients to their healthcare provider for treatment-related advice

SECTION A: CONSENT TO SHARE HEALTH INFORMATION FOR PATIENT SUPPORT SERVICES

By signing this Patient Consent Form (PCF), I hereby authorize my healthcare providers, health insurance carriers, laboratory providers, and pharmacy providers (collectively, Healthcare Entities) to use and disclose my individual health and identifying information, including but not limited to health insurance information, medical diagnosis and condition (including but not limited to laboratory test results such as diagnostic results as well as test results related to diagnosis or supportive testing), prescription information, and name, date of birth, sex, address, and telephone number to BioMarin and its agents and representatives, including but not limited to third parties authorized by BioMarin, for them to use for the purposes listed below. I further authorize BioMarin to use my individual health and identifying information to administer the patient support program through BioMarin RareConnections™. Authorized purposes:

- to assist me with accessing services that support my treatment;
- to contact my healthcare provider and collect, enter, and maintain my health information in a database;
- to contact my insurers as needed to verify my insurance coverage, review reimbursement requirements, verify other financial assistance for which I might be eligible, assist with the processing of claims, or otherwise assist in obtaining coverage or financial assistance for my treatment, including but not limited to in relation to post-administration monitoring (n/a for Veteran’s Administration (VA) patients);
- to determine eligibility for program offerings, including but not limited to financial assistance services (financial assistance n/a for VA patients);
- to determine eligibility for a BioMarin Co-Pay Assistance program, valid ONLY for qualifying patients residing in the 50 U.S. states or in Puerto Rico, where not prohibited by law, with commercial insurance, who are not a government beneficiary and/or participant in a federal or state-funded health insurance program, and who have a valid prescription for an FDA-approved indication for the qualifying BioMarin therapy; the BioMarin Co-Pay Assistance program pays for eligible out-of-pocket costs, where applicable, associated with a qualifying BioMarin therapy up to a maximum amount per calendar year;
- to contact me to follow up on any BioMarin RareConnections enrollment requirements, discuss and provide information and education on my treatment and any follow-up requirements, discuss the effectiveness of patient support services, and provide patient support services, education, and adherence reminders such as to take my BioMarin medication; and
- if I sign under Section 3, I further authorize BioMarin to use my individual and health and identifying information for the purposes described in Section B.

Once my health information has been disclosed to BioMarin, I understand that certain federal privacy laws may no longer protect the information. However, BioMarin intends to protect my health information by using and disclosing it only for purposes described in this PCF or as permitted by law or regulations. California residents, to learn more about the information BioMarin may collect about you, how we use that information, and your rights under the California Consumer Privacy Act (CCPA), please review our CCPA Privacy Policy, available at biomarin.com/data-privacy-center. I understand that pharmacy providers, or others working on their behalf, may receive remuneration from BioMarin in exchange for patient therapy support services and data provided.

I understand that any product(s) provided under BioMarin’s temporary Bridge Support program are for my/my child’s personal use and will not be sold, traded, bartered, or transferred. Completing this form does not guarantee that I/my child will qualify for BioMarin’s temporary Bridge Support program. In the event I become eligible for BioMarin’s temporary Bridge Support program, I understand and agree as follows:

- BioMarin Bridge is not health insurance and is available for eligible patients only.
- Offer is available only to patients who have been diagnosed with an FDA-approved indication for a BioMarin therapy.
- No claim for reimbursement for product dispensed pursuant to this program may be submitted to my prescription insurance provider or any other third-party payer, including Medicare.
- To be eligible for Bridge, I/my child must be actively pursuing coverage through my insurance or awaiting a prior authorization/appeal decision.
- BioMarin Bridge does not require, nor will be made contingent on, purchase requirements of any kind.
- BioMarin reserves the right to amend, rescind, or discontinue this program at any time without notification.
- BioMarin Bridge can be dispensed only by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process or a new-to-market block by the payer has been confirmed.

- BioMarin Bridge is available only to patients in the U.S. and Puerto Rico.
- Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico.
- Additional eligibility criteria may apply. Contact BioMarin RareConnections for details.

This PCF expires in ten (10) years, or such shorter amount of time required by applicable state law, after the date I sign it as indicated by the date next to my signature, unless otherwise canceled earlier as set forth below. I understand I have a right to receive a copy of this PCF.

I understand that I may refuse to sign this PCF. I further understand that my treatment (including with a BioMarin product), payment for treatment, insurance enrollment, or eligibility for insurance benefits are not conditioned upon my agreement to sign this PCF, but if I do not sign it, or if I later cancel it, I will not be able to receive BioMarin's patient support services.

I understand that I may cancel this PCF at any time by mailing a letter to BioMarin at BioMarin RareConnections at 680 Century Point, Lake Mary, FL 32746 or emailing support@biomarin-rareconnections.com. Canceling this PCF will end my consent for my Healthcare Entities to further use and disclose my health information to BioMarin after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this PCF. Canceling this PCF will not affect my ability to receive treatment, payment for treatment, or my eligibility for health insurance.

SECTION B: CONSENT FOR MARKETING/OTHER COMMUNICATIONS

By signing this Patient Consent Form (PCF), I hereby authorize my Healthcare Entities to use and disclose my individual health and identifying information to BioMarin for marketing purposes or to otherwise provide me with information about BioMarin products, services, research, clinical trials, and programs or other topics of interest, and to conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that BioMarin and companies working with BioMarin may use my individual health and identifying information to contact me by mail, email, fax, telephone call, or text message for these purposes. I understand and agree that any information that I provide may be used by BioMarin to help develop new products, services, and programs. I further understand that BioMarin will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.

1 To authorize your consent, please complete all fields below.

Patient's First Name _____ Middle Initial _____ Patient's Last Name _____ Suffix _____ Date of Birth _____ Gender Male Female Other

Patient's/Authorized Representative's Name (if applicable) _____ Relationship to Patient _____

Patient's/Authorized Representative's Address _____ Floor/Suite/Unit _____ City _____ State _____ ZIP Code _____

Preferred Method of Contact (please specify) Primary Phone _____

Mobile Phone (leave blank if mobile is primary phone) _____ Email _____

Preferred Language English Spanish Other Language (please specify) _____

2 Please read and sign below.

I have read and understand Section A in this PCF, the Consent to Share Health Information for Patient Support Services, and agree to the terms stated therein. A consent signature is required in order to receive BioMarin services.

Patient's/Authorized Representative's Signature _____ Date _____

Print Authorized Representative's Name (if applicable) _____ Relationship to Patient _____

3 Please read and sign below.

I have read and understand Section B in this PCF, the Consent for Marketing/Other Communications, and agree to the terms stated therein.

Patient's/Authorized Representative's Signature _____ Date _____

Print Authorized Representative's Name (if applicable) _____ Relationship to Patient _____

Print and fax your completed form (both pages) to 1.888.863.3361.

Note for healthcare providers: once your patient has completed this form, provide a copy to them and place the original in the patient's medical record.